This site uses third parties to own and optimize your navigation and perform analytical work cookies. If you continue browsing, consider that you accept its use.
You can learn more at our Cookie Policy.


EPO patent granted

Innoprot is pleased to announce the granting of EPO (European Patent Office) patent on its core GPCR Screening technology on June 7th 2017.
Innoprot received notice of the granting of EPO (European Patent Office) patent on its core technology for GPCR Screening. This broadens proprietary protection of the company’s core technology to all European countries.

This technology called “NOMAD” comprises a novel family of fluorescent biosensors for measuring GPCR activity in living cells through the G-Protein signaling pathway. Each biosensor of the family (co-expressed in a cell line with a label-free GPCR of interest), provides an innovative and sensitive research tool for studying the molecular mechanism and kinetics underlying the GPCR activation. NOMAD biosensors allow the measurement of second messenger concentrations changes promoted by GPCR activation. An increase in the second messenger concentration leads to a change in the structural folding of NOMAD biosensor that fosters its cellular relocation and fluorescence increase.

More information

© Innoprot 2008 - Cell Based Assays for Drug Discovery Screening - Política de cookies